These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 26569509

  • 1. Valrubicin in refractory non-muscle invasive bladder cancer.
    Sharma P, Zargar-Shoshtari K, Sexton WJ.
    Expert Rev Anticancer Ther; 2015; 15(12):1379-87. PubMed ID: 26569509
    [Abstract] [Full Text] [Related]

  • 2. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP, Greenberg RE, Steinberg GD.
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
    Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ.
    Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
    [Abstract] [Full Text] [Related]

  • 5. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL, Solsona E, Unda M, Beardo P, Rodríguez-Molina J, Chantada V, Palou J, Muntañola P, Alonso Dorrego JM, Pérez-Garcia FJ, Silva JM, Chesa N, Montesinos M, Ojea A, Madero R, Martínez-Piñeiro JA.
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P, Turkeri L.
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [Abstract] [Full Text] [Related]

  • 8. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, Oosterlinck W.
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [Abstract] [Full Text] [Related]

  • 9. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG, Neulander E, Murphy WM, Wajsman Z.
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [Abstract] [Full Text] [Related]

  • 10. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.
    Smaldone MC, Gayed BA, Tomaszewski JJ, Gingrich JR.
    Minerva Urol Nefrol; 2009 Jun; 61(2):71-89. PubMed ID: 19451890
    [Abstract] [Full Text] [Related]

  • 11. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE.
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intravesical therapy for bladder cancer.
    Williams SK, Hoenig DM, Ghavamian R, Soloway M.
    Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
    [Abstract] [Full Text] [Related]

  • 14. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
    McElree IM, Packiam VT, Steinberg RL, Mott SL, Gellhaus PT, Nepple KG, O'Donnell MA.
    J Urol; 2022 Nov; 208(5):969-977. PubMed ID: 35830552
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.
    Marchetti A, Wang L, Magar R, Grossman HB, Lamm DL, Schellhammer PF, Erwin-Toth P.
    Clin Ther; 2000 Apr; 22(4):422-38. PubMed ID: 10823364
    [Abstract] [Full Text] [Related]

  • 17. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

  • 18. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D, Brausi M, O'Donnell MA, Witjes JA.
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [Abstract] [Full Text] [Related]

  • 19. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
    Barlow L, McKiernan J, Sawczuk I, Benson M.
    BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
    [Abstract] [Full Text] [Related]

  • 20. Medical management of patients with refractory carcinoma in situ of the bladder.
    Kim JC, Steinberg GD.
    Drugs Aging; 2001 Oct; 18(5):335-44. PubMed ID: 11392442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.